We are excited to announce one of our speakers for the 8th Annual Viral Safety and Viral Clearance Summit. Don’t miss your chance to hear from Alyssa LoVullo on next-generation MMV stock impact on small-scale viral filter performance. Learn more about the agenda and register here: https://okt.to/KftVFT #viralclearance #viralsafety #CGT #viralsummit24 #biologicstesting Alyssa Driscoll
Exciting!
Warning signature, smallpox. In this real world example, the involved community 1) had prior experience diagnosing smallpox, 2) had rapid access to laboratory validation, and 3) had full authority and public cooperation to quickly execute countermeasures and bring the epidemic to a halt. How would this signature differ in today's society? #biodefense #healthsecurity #emergencymanagement #hospitalpreparedness #nationalsecurity
Just a few days to go until our webinar, Overcoming Contamination Risks During Biological Production: Mycoplasma & Virus Testing. 🎤 Sholto Russell Russel invites you to join him, Richard Adair, and Jean-Jacques Derriche for an insightful conversation, in his short video. 📽️ Register here 👉 https://lnkd.in/eUV_RaJP #drugdevelopment
Gene Therapy, RNA, Cancer Vaccines & OV Drug Development | Advance Therapeutics | Competitive & Scientific Intelligence
🔬 Exciting Developments in OV Drug Landscape! 🔬 In just the first few months of 2024, we've witnessed 30 new OV drugs disclosed and 14 new trials initiated. Navigating this dynamic landscape can be daunting, but strategic decision-making backed by comprehensive data can significantly mitigate risks and potential failures as you enter the clinic. Curious about what 2023 brought to the table? Dive into our comprehensive landscape review utilizing data from our OV-dedicated database below 👇 If you are currently developing OV drugs, drop me a message. I'm here to provide tailored insights to help accelerate your drug development. #oncolyticviruses #drugdevelopment
Unlock the 2023 Oncolytic Viruses Drug Landscape! Get your copy for a comprehensive review of 2023 by viral family and an analysis of discontinued assets. Discover how the Rhabdoviridae family has defied expectations, emerging as the fastest-growing group. Access now https://ter.li/ywglm5
Platinum wellness advocate and leader with dōTERRA International, the largest essential oil company in the world.
It’s prime time for YOU! 🥳 DDR Prime Cellular Complex is here to protect, support, and renew.* This game changer provides Frankincense, Wild Orange, Litsea, Thyme, Clove, Summer Savory, Niaouli, and Lemongrass essential oils. Learn more about DDR Prime at https://lnkd.in/gerEZdEq *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. https://lnkd.in/g_dkDhdQ
The SensiTox B. anthracis Toxin Test from partner First Light Diagnostics is the latest FDA 510(k) clearance for BARDA-supported products. This clearance helps bolster national preparedness and protect people during a public health emergency involving anthrax. With the SensiTox B. anthracis Toxin Test, clinicians can rapidly screen large numbers of people potentially exposed to anthrax, identify those infected, and quickly initiate antibiotic treatment. This helps improve patient outcomes and mitigate the impacts of deliberate or naturally occurring outbreaks of biological threats. The success of this program demonstrates the value of collaborative public private partnerships between the U.S. government and product development partners to protect national #HealthSecurity. Learn more: https://ow.ly/O28E50Qlx1u
Discover the Versatility of Biozen dSEC-7 Amidst Mobile Phase Changes for In-Depth Aggregate Analysis of Adeno-Associated Virus Capsids! In this technical note, Biozen dSEC-7 proves instrumental in quickly and accurately resolving AAV monomer from aggregates in under 10 minutes, showcasing consistent results across different mobile phase conditions. Read the full note: https://lnkd.in/gRuHfEVE
There are eight major changes to CLSI M100: Performance Standards for Antimicrobial Susceptibility Testing, 34th Edition. Pre-order the document here >> https://ow.ly/x6bs50QBh3q.
Ahead of the release of CLSI M100: Performance Standards for Antimicrobial Susceptibility Testing, read through the eight major changes to the 34th edition. Preorder this edition ahead of its Spring 2024 release here >> https://ow.ly/Aynu50QGfMY.
👏